[TENAGA] QoQ TTM Result on 31-May-2013 [#3]

Announcement Date
18-Jul-2013
Admission Sponsor
-
Sponsor
-
Financial Year
31-Aug-2013
Quarter
31-May-2013 [#3]
Profit Trend
QoQ- 23.68%
YoY- 81.61%
Quarter Report
View:
Show?
TTM Result
28/02/14 30/11/13 31/08/13 31/05/13 28/02/13 30/11/12 31/08/12 CAGR
Revenue 38,719,500 37,573,000 37,131,400 36,963,300 36,506,800 36,284,800 35,848,400 5.28%
PBT 5,220,000 5,506,800 5,892,800 7,020,700 5,944,300 7,837,100 5,821,100 -7.02%
Tax 919,300 160,700 -542,300 -1,519,900 -1,515,300 -1,926,200 -1,402,000 -
NP 6,139,300 5,667,500 5,350,500 5,500,800 4,429,000 5,910,900 4,419,100 24.58%
-
NP to SH 6,131,500 5,669,700 5,334,900 5,468,000 4,421,000 5,900,100 4,410,500 24.63%
-
Tax Rate -17.61% -2.92% 9.20% 21.65% 25.49% 24.58% 24.08% -
Total Cost 32,580,200 31,905,500 31,780,900 31,462,500 32,077,800 30,373,900 31,429,300 2.43%
-
Net Worth 33,864,819 36,848,281 33,411,167 34,930,320 33,661,555 33,138,447 32,795,009 2.16%
Dividend
28/02/14 30/11/13 31/08/13 31/05/13 28/02/13 30/11/12 31/08/12 CAGR
Div 1,399,692 1,386,927 1,386,927 1,371,523 1,371,523 1,097,630 1,097,630 17.64%
Div Payout % 22.83% 24.46% 26.00% 25.08% 31.02% 18.60% 24.89% -
Equity
28/02/14 30/11/13 31/08/13 31/05/13 28/02/13 30/11/12 31/08/12 CAGR
Net Worth 33,864,819 36,848,281 33,411,167 34,930,320 33,661,555 33,138,447 32,795,009 2.16%
NOSH 5,644,136 5,643,786 5,568,527 5,537,463 5,516,478 5,505,640 5,465,834 2.16%
Ratio Analysis
28/02/14 30/11/13 31/08/13 31/05/13 28/02/13 30/11/12 31/08/12 CAGR
NP Margin 15.86% 15.08% 14.41% 14.88% 12.13% 16.29% 12.33% -
ROE 18.11% 15.39% 15.97% 15.65% 13.13% 17.80% 13.45% -
Per Share
28/02/14 30/11/13 31/08/13 31/05/13 28/02/13 30/11/12 31/08/12 CAGR
RPS 686.01 665.74 666.81 667.51 661.78 659.05 655.86 3.05%
EPS 108.63 100.46 95.80 98.75 80.14 107.16 80.69 21.98%
DPS 25.00 24.57 25.00 25.00 25.00 20.09 20.09 15.73%
NAPS 6.00 6.529 6.00 6.308 6.102 6.019 6.00 0.00%
Adjusted Per Share Value based on latest NOSH - 5,537,463
28/02/14 30/11/13 31/08/13 31/05/13 28/02/13 30/11/12 31/08/12 CAGR
RPS 666.09 646.37 638.77 635.88 628.03 624.21 616.70 5.28%
EPS 105.48 97.54 91.78 94.07 76.05 101.50 75.87 24.64%
DPS 24.08 23.86 23.86 23.59 23.59 18.88 18.88 17.66%
NAPS 5.8258 6.339 5.7477 6.0091 5.7908 5.7008 5.6417 2.16%
Price Multiplier on Financial Quarter End Date
28/02/14 30/11/13 31/08/13 31/05/13 28/02/13 30/11/12 31/08/12 CAGR
Date 28/02/14 29/11/13 30/08/13 31/05/13 28/02/13 30/11/12 30/08/12 -
Price 12.00 9.86 8.73 8.35 6.94 6.94 6.84 -
P/RPS 1.75 1.48 1.31 1.25 1.05 1.05 1.04 41.60%
P/EPS 11.05 9.81 9.11 8.46 8.66 6.48 8.48 19.35%
EY 9.05 10.19 10.97 11.83 11.55 15.44 11.80 -16.25%
DY 2.08 2.49 2.86 2.99 3.60 2.89 2.94 -20.65%
P/NAPS 2.00 1.51 1.45 1.32 1.14 1.15 1.14 45.61%
Price Multiplier on Announcement Date
28/02/14 30/11/13 31/08/13 31/05/13 28/02/13 30/11/12 31/08/12 CAGR
Date 24/04/14 23/01/14 31/10/13 18/07/13 18/04/13 23/01/13 31/10/12 -
Price 11.94 11.50 9.43 9.01 7.95 6.96 6.95 -
P/RPS 1.74 1.73 1.41 1.35 1.20 1.06 1.06 39.28%
P/EPS 10.99 11.45 9.84 9.12 9.92 6.49 8.61 17.72%
EY 9.10 8.74 10.16 10.96 10.08 15.40 11.61 -15.02%
DY 2.09 2.14 2.65 2.77 3.14 2.89 2.89 -19.47%
P/NAPS 1.99 1.76 1.57 1.43 1.30 1.16 1.16 43.44%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment